Kereos, Inc
 
 

Product Pipeline - Targeted Therapy for Cancer


Targeted Chemotherapeutics

Kereos incorporates its unique nanotechnology to target tumors for delivery and activation of therapeutic payloads. This approach has the potential to improve efficacy and minimize the toxic side effects observed in previous cancer therapies.

KER-1001

Kereos’ lead cancer therapeutic incorporates paclitaxel, a major cancer therapeutic drug, into the targeted nanodroplet. The anti-tumor properties of paclitaxel have been known for many years; however it has certain side effects that limit dosage and efficacy. Targeted delivery of paclitaxel may increase efficacy and reduce side effects.

 


KER-1002

Kereos is also developing a cancer therapeutic that incorporates a natural product that has been shown to have excellent anti-tumor efficacy in preclinical studies. Unfortunately this product is highly toxic when administered as a free drug product. By incorporating this product into the Kereos formulation, it has been shown to have efficacy in vitro and reduced side effects in vivo at doses above historical lethal doses.


KER-1003

KER-1003 provides another example of how the Kereos targeted nanodroplet technology allows the use of promising therapeutics that have not been developed due to side effects and molecular fragility. KER-1003 consists of one of the Kereos base formulations and incorporates another well known natural product that is very effective as an anti-angiogenic. When used as a solo drug, this product degrades quickly and is very toxic. Based on the success shown with KER-1001 and 1002, Kereos feels that this natural product can be successfully developed as an efficacious and minimally toxic therapeutic. .


Future Opportunities

Based on the results that have been observed in the in vitro and in vivo studies conducted for KER-1001 and KER-1002, Kereos feels that this is an opportunity for other existing drugs to be reformulated for improved performance. In addition, emerging therapeutics that are stalled in development due to toxicity or lack of efficacy may be revived and successfully developed. This will provide new opportunities for partnering and new prospects for meeting unmet medical needs. .


Diagnosis, Progression of Disease, and Assessment of Treatment

KER 0001

As a diagnostic application of the Kereos technology platform, the KER-0001 product uses both the ανβ3 integrin biomarker and Fluorine-19 imaging to detect the presence of angiogenesis. Angiogenesis is an important factor in the progression of cancer, cardiovascular disease and autoimmune disorders. The Kereos therapeutic products can also be imaged by MRI to confirm delivery of the therapeutic payload to the target, and assess clinical response.

In other words, the imaging characterisitics of the nanodroplet can be used to not only diagnose disease but it can also be used as a tool to assess the stage of the disease and the effectiveness of treatment. The figure below provides a three-dimensional view of a tumor and the tumor vasculature. The imgages allow for the monitoring of the progression of the vasculature and tumor size over time.


Angiogensis

>l>>l>>